Sanofi polishes rare disease profile as Niemann-Pick drug scores promising PhII/III data — there's just one question
Two years after it entered Sanofi’s R&D spotlight, an enzyme replacement therapy has come through in a pivotal study — paving the way for regulatory submissions in 2021 after the drugmaker answers one remaining question.
Rare disease continues to be a stated focus under new CEO Paul Hudson even as he executes a drastic shakeup on the pipeline, excising diabetes and cardio research while burnishing oncology.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.